Page 40 - 2022_01-Haematologica-web

D. Qualls and G. Salles
imab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516-2522.
13. Maurer MJ, Bachy E, Ghesquières H, et al. Early event status informs subsequent out- come in newly diagnosed follicular lym- phoma. Am J Hematol. 2016;91(11):1096- 1101.
14. Moccia AA, Schär S, Hayoz S, et al. Prognostic value of POD24 validation in fol- licular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK). Br J Haematol. 2021;192 (6):1031-1034.
15. Binkley MS, Brady JL, Hajj C, et al. Salvage treatment and survival for relapsed follicular lymphoma following primary radiotherapy: a collaborative study on behalf of ILROG. Int J Radiat Oncol Biol Phys. 2019;104 (3):522.
16. Casulo C, Barr PM. How I treat early-relaps- ing follicular lymphoma. Blood. 2019;133 (14):1540-1547.
17. Wagner-Johnston ND, Link BK, Byrtek M, et al. Outcomes of transformed follicular lym- phoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 2015;126(7):851-857.
18. Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus flu- darabine plus rituximab for patients with relapsed indolent and mantle-cell lym- phomas: a multicentre, randomised, open- label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17(1):57-66.
19.Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non- Hodgkin lymphoma (GADOLIN): a ran- domised, controlled, open-label, multicen- tre, phase 3 trial. Lancet Oncol. 2016;17(8):1081-1093.
20. Cheson BD, Chua N, Mayer J, et al. Overall survival benefit in patients with rituximab- refractory indolent non-hodgkin lymphoma who received obinutuzumab plus ben- damustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018;36(22):2259-2266.
21. Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy with obinu- tuzumab or rituximab for previously untreated follicular lymphoma in the GAL- LIUM study: Influence of chemotherapy on efficacy and safety. J Clin Oncol. 201836(23):2395-2404.
22. Link BK, Day B-M, Zhou X, et al. Second- line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol. 2019;184(4):660-663.
23. Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: sur- vival, treatment outcomes, and identifica- tion of high-risk subgroups. Blood Cancer J. 2020;10(7):74.
24. Weide R, Feiten S, Friesenhahn V, et al. Retreatment with bendamustine-containing regimens in patients with relapsed/refracto- ry chronic lymphocytic leukemia and indo- lent B-cell lymphomas achieves high response rates and some long lasting remis- sions. Leuk Lymphoma. 2013;54(8):1640- 1646.
25. Morschhauser F, Fowler NH, Feugier P, et al.
Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379(10):934-947.
26. Strati P, Samaniego F, Gallardo M, Noorani M. Treatment and outcome of patients with follicular lymphoma relapsed or progressed after frontline lenalidomide and rituximab. Blood. 2020;136(Suppl 1):31-32.
27. Harrop S, Polliack A, Tam CS. Chronic lym- phoproliferative disorders and secondary cancers in the era of purine analogues and beyond. Leuk Lymphoma. 2020;62(4):771- 778.
28. Ghione P, Cavallo F, Visco C, et al. A retro- spective study of R-DHAP/Ox for early pro- gressing follicular lymphoma. Br J Haematol. 2018;183(5):828-831.
29. Martinelli G, Montoro J, Vanazzi A, et al. Chlorambucil–rituximab as first-line thera- py in patients affected by follicular non- Hodgkin’s lymphoma: a retrospective sin- gle-centre study. Hematol Oncol. 2015;33 (4):129-135.
30. Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lym- phomas: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2016;21 (1):5-15.
31. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R- FCM) in patients with recurring and refrac- tory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108(13):4003- 4008.
32. Van Oers MHJ, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized inter- group study. J Clin Oncol. 2010;28(17):2853- 2858.
33. Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance improves overall survival of patients with follicular lym- phoma—individual patient data meta-analy- sis. Eur J Cancer. 2017;76:216-225.
34. Schouten HC, Qian W, Kvaloy S, et al. High- dose therapy improves progression-free sur- vival and survival in relapsed follicular non- Hodgkin’s lymphoma: results from the ran- domized European CUP trial. J Clin Oncol. 2003;21(21):3918-3927.
35. le Gouill S, de Guibert S, Planche L, et al. Impact of the use of autologous stem cell transplantation at first relapse both in naïve and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica. 2011;96(8):1128-1135.
36. Jurinovic V, Metzner B, Pfreundschuh M, et al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 random- ized trials from the German Low Grade Lymphoma Study Group. Biol Blood Marrow Transplant. 2018;24(6):1172-1179.
37. Casulo C, Friedberg JW, Ahn KW, et al. Autologous transplantation in follicular lym- phoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research analysis. Biol Blood Marrow Transplant. 2018;24(6):1163-1171.
38. Pettengell R, Uddin R, Boumendil A, et al.
Durable benefit of rituximab maintenance post-autograft in patients with relapsed fol- licular lymphoma: 12-year follow-up of the EBMT Lymphoma Working Party Lym1 trial. Bone Marrow Transplant. 2021;56(6): 1413-1421.
39. Sarkozy C, Trneny M, Xerri L, et al. Risk fac- tors and outcomes for patients with follicu- lar lymphoma who had histologic transfor- mation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34(22):2575-2582.
40. El-Najjar I, Boumendil A, Luan JJ, et al. The impact of total body irradiation on the out- come of patients with follicular lymphoma treated with autologous stem-cell transplan- tation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. Ann Oncol. 2014;25(11):2224-2229.
41. Hoskin P, Popova B, Schofield O, et al. 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2021;22(3):332-340.
42. Illidge T, Morschhauser F. Radioimmunotherapy in follicular lym- phoma. Best Pract Res Clin Haematol. 2011;24(2):279-293.
43. Kolstad A, Illidge T, Bolstad N, et al. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2020;4(17):4091.
44. Phillips TJ, Michot JM, Ribrag V. Can next- generation PI3K inhibitors unlock the full potential of the class in patients with B-cell lymphoma? Clin Lymphma Myeloma Leuk. 2021;21(1):8-20.
45. Salles G, Schuster SJ, De Vos S, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent- refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica. 2017;102(4):e156-e159.
46. Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008-1018.
47. Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019;37(11):912-922.
48. Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol. 2021;39(15):1609- 1618.
49. Dreyling M, Santoro A, Mollica L, et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year fol- low-up of the CHRONOS-1 study. Am J Hematol. 2020;95(4):362-371.
50.Gopal AK, Kahl BS, Flowers CR, et al. Idelalisib is effective in patients with high- risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood. 2017;129(22):3037-3039.
51. Lynch R, Paneesha S, Avigdor A, et al. Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory follicular lymphoma (CITADEL- 203). Blood. 2020;136(Suppl 1):36-37.
52. Zelenetz AD, Jagadeesh D, Reddy NM, et al. Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL). J Clin Oncol. 2019;37(15_suppl):7512.
53.Matasar MJ, Capra M, Özcan M, et al. Copanlisib plus rituximab versus placebo
32
haematologica | 2022; 107(1)